Programs and Events

Many MDF community members are aware of an important, multi-year MDF effort -- MDF 3.0: Accelerating Drug Development -- because we published an article on the launch of this initiative in early 2015. Read a full report on the first-year results of MDF 3.0: Accelerating Drug Development, and the initiatives we are pursuing to promote the development of new DM therapies.  

Researchers from the University of Rochester recently published a paper examining the symptoms and impact of myotonic dystrophy type 2 (DM2). They found that the most commonly reported symptoms of DM2 are not, in fact, the ones that have the highest reported impact on daily living.

As part of our investment in the development of effective treatments for myotonic dystrophy, MDF is helping develop what is called "benefit/risk" information for regulatory agencies reviewing potential therapies.

In honor of National Family Caregivers Month, and to celebrate the many critically important caregivers in the MDF community, we’ve taken a look at the status of caregiving today. 

The MDF 3.0 Roadmap is available for your review. MDF has pledged our resources to a number of significant aimed at accelerating Care and a Cure for the next three years.

To support myotonic dystrophy drug development efforts, MDF held a science workshop in September 2014 at our annual conference. The workshop brought together more than 50 DM researchers and industry representatives from around the world to review where we are in the development of clinical trial endpoint measures for DM.

Join the Myotonic Dystrophy Family Registry and help accelerate myotonic dystrophy research and drug development!